Practice Management

Payment Terms for Aflibercept Injection Extended in Response to COVID-19

Posted on

Regeneron will temporarily extend physician payment terms from 100 days to 150 days for Eylea (aflibercept) Injection purchases from authorized distributors due to the COVID-19 outbreak, according to a press release by the American Academy of Ophthalmology.

The new temporary terms are expected to be implemented by April 1, 2020 and will retroactively apply to purchases of aflibercept on or after March 1, 2020.

“The COVID-19 pandemic is having a significant impact on patients and ophthalmologists. In some cases, it is limiting patient access to essential care,” said Anne L. Coleman, MD, PhD, president of the American Academy of Ophthalmology in a press release. “We will continue to work with the healthcare community to find ways to help our patients and colleagues get through this difficult time. Regeneron’s prompt response to their needs will be extraordinarily beneficial.”

Read the full press release here

Related Articles
New Patient Financial Engagement Services improves patient payments
Jul 28, 2021
Study identifies patient characteristics linked with appointment no-shows
Mar 02, 2021
Ethics & Professionalism: Road to the Future of Eye Care
Feb 18, 2021